News

Medigene's Drug Veregen® receives market approval in Canada

 

 

Martinsried/Munich, 10 September 2013. Medigene AG (MDG, Frankfurt, Prime Standard) announced today that its drug Veregen® for the treatment of genital warts has obtained market approval in Canada. Market launch of Veregen® by Medigene's partner Triton Pharma is scheduled to take place during the first half of 2014.

Veregen® is already being marketed in the USA (by Fougera), in Germany, Austria and Switzerland (by Abbott), in Spain (by Bial), in Serbia (by Pharmanova) as well as in the Netherlands (by Will-Pharma) and approved in further countries. The launch of Veregen® in several other countries is expected until the end of 2013. Medigene has entered into numerous marketing partnerships for Veregen® across Europe, Asia, and America, and is planning to continue this global licensing strategy to further leverage the product's market potential.

About Veregen®: Veregen®, a topical treatment for external genital or perianal warts, contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. In its current treatment guidelines for sexually transmitted diseases, the US Center for Disease Control and Prevention recommends Sinecatechins 15% ointment (Veregen®) as a possible option for treating genital warts. In addition, Sinecatechins 10% & 15% ointment (Veregen®) has been included in the current European guideline on the treatment of genital warts, the 2012 European Guideline for the Management of Anogenital Warts.

Triton Pharma Inc.: The Canadian Company Triton Pharma, founded in 2001, specializes in the commercialization of prescription drugs in gynecology (women's health), urology, and dermatology. With proprietary and licensed products on the market, the company is successfully positioning itself as the ideal partner for Companies wishing to establish their products in Canada. Further information can be obtained at: www.tritonpharma.ca.

Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene was the first German biotech company to have revenues from marketed products, which are distributed by partner companies. It has two drug candidates in clinical trials, EndoTAG®-1 and RhuDex®, and is developing an innovative vaccine technology. For more information, please visit www.medigene.com.

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.

Contact

Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please go to www.medigene.com/unsubscribe.